This Covid19-focused symposium will bring together scientists pushing the boundaries of drug discovery to find remedies for ongoing Covid-19 pandemic and future epidemics. We will hear about how basic research in drug discovery has been taken to clinical practice, get examples of ongoing clinical trials and increase our understanding of suitable animal models. The event will include a panel discussion with presenters about current challenges to find a drug for Covid-19.
Registration required. Participation is limited to 300 participants.
Chairmen: Anna-Lena Gustavsson and Johan Lennerstrand
|14.00||Welcome and Introduction to the SciLifeLab Covid-19 Research Program|
Olli Kallioniemi, Director SciLifeLab
|14.10||Drug Discovery and studies of drug targets for COVID-19 in SciLifeLabs Covid-19 Research Program, |
Anna-Lena Gustavsson, SciLifeLab
|14.20||Clinical trials on antivirals – what has been done and what is expected to come|
Daniel Kuritzkes, Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital, Boston, USA
|15.00||Identification of drug repurposing candidates for the ANTICOV study|
Peter Sjö, Discovery Project Leader, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland
|15.40||Animal models for emerging coronavirus, progress and new insights|
Johan Neyts, Professor of Virology, University of Leuven, Belgium
|16.15||Panel Discussion how has the pandemic changed the landscape? What are the current challenges in drug discovery to clinical implementation?|
|16:45||Wrap up and final words. End at 17:00|
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.